Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 84%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
2,741
Total Claims
$4.9M
Drug Cost
384
Beneficiaries
$13K
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+14%
Opioid rate vs peers
7.2% vs 6.3% avg
-6%
Cost per patient vs peers
$13K vs $14K avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
7.2%
Opioid Rate
196
Opioid Claims
$12K
Opioid Cost
20.9%
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 2,083 claims · $532K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 61 | $1.2M |
| Enzalutamide | 52 | $684K |
| Pomalidomide | 13 | $300K |
| Abiraterone Acetate | 79 | $299K |
| Ruxolitinib Phosphate | 26 | $292K |
| Pralsetinib | 12 | $239K |
| Palbociclib | 16 | $230K |
| Acalabrutinib Maleate | 15 | $202K |
| Apixaban | 162 | $179K |
| Dabrafenib Mesylate | 11 | $146K |
| Rivaroxaban | 102 | $100K |
| Lapatinib Ditosylate | 18 | $55K |
| Enoxaparin Sodium | 30 | $20K |
| Anastrozole | 191 | $7,738 |
| Exemestane | 19 | $6,702 |
Prescribing Profile
Patient Profile
77
Avg Age
56%
Female
2.22
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About